Literature DB >> 26567289

TLR7 and TLR9 ligands regulate antigen presentation by macrophages.

Teja Celhar1, Selma Pereira-Lopes2, Susannah I Thornhill1, Hui Yin Lee1, Manprit K Dhillon1, Michael Poidinger1, John E Connolly3, Lina H K Lim4, Subhra K Biswas1, Anna-Marie Fairhurst5.   

Abstract

The toll-like receptors (TLRs) are important innate receptors recognizing potentially pathogenic material. However, they also play a significant role in the development of Alzheimer's disease, cancer, autoimmunity and the susceptibility to viral infections. Macrophages are essential for an effective immune response to foreign material and the resolution of inflammation. In these studies, we examined the impact of different TLR ligands on macrophage cell function. We demonstrate that stimulation of all TLRs tested increases the phagocytosis of apoptotic cells by macrophages. TLR7 and TLR9 ligation decreased the levels of the surface co-expression molecules CD86 and MHCII, which was associated with a concomitant reduction in antigen presentation and proliferation of T cells. This down-regulation in macrophage function was not due to an increase in cell death. In fact, exposure to TLR7 or TLR9 ligands promoted cell viability for up to 9 days, in contrast to TLR3 or TLR4. Additionally, macrophages exposed to TLR7/TLR9 ligands had a significantly lower ratio of Il-12/Il-10 mRNA expression compared with those treated with the TLR4 ligand, LPS. Taken together, these data demonstrate that TLR7/TLR9 ligands push the macrophage into a phagocytic long-lived cell, with a decreased capacity of antigen presentation and reminiscent of the M2 polarized state. © The Japanese Society for Immunology. 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  TLR; activation; antigen presentation; macrophages

Mesh:

Substances:

Year:  2015        PMID: 26567289      PMCID: PMC4888346          DOI: 10.1093/intimm/dxv066

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  40 in total

1.  CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing.

Authors:  R S Chu; D Askew; E H Noss; A Tobian; A M Krieg; C V Harding
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

Review 2.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

3.  Biochemical and functional characterization of three activated macrophage populations.

Authors:  Justin P Edwards; Xia Zhang; Kenneth A Frauwirth; David M Mosser
Journal:  J Leukoc Biol       Date:  2006-08-11       Impact factor: 4.962

4.  Different cytokines modulate ubiquitin gene expression in rat skeletal muscle.

Authors:  M Llovera; N Carbó; J López-Soriano; C García-Martínez; S Busquets; B Alvarez; N Agell; P Costelli; F J López-Soriano; A Celada; J M Argilés
Journal:  Cancer Lett       Date:  1998-11-13       Impact factor: 8.679

5.  Bacterial/CpG DNA down-modulates colony stimulating factor-1 receptor surface expression on murine bone marrow-derived macrophages with concomitant growth arrest and factor-independent survival.

Authors:  D P Sester; S J Beasley; M J Sweet; L F Fowles; S L Cronau; K J Stacey; D A Hume
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  Bone Marrow-Derived Macrophages (BMM): Isolation and Applications.

Authors:  Joachim Weischenfeldt; Bo Porse
Journal:  CSH Protoc       Date:  2008-12-01

7.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

8.  Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors.

Authors:  L Maródi; S Schreiber; D C Anderson; R P MacDermott; H M Korchak; R B Johnston
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Effects of IL-4 on macrophage functions: increased uptake and killing of a protozoan parasite (Trypanosoma cruzi).

Authors:  J J Wirth; F Kierszenbaum; A Zlotnik
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

10.  TRAIL is involved in CpG ODN-mediated anti-apoptotic signals.

Authors:  Eun-Jung Lim; Dae-Weon Park; Tae-Whal Jeong; Byung-Rho Chin; Yoe-Sik Bae; Suk-Hwan Baek
Journal:  Oncol Rep       Date:  2011-12-06       Impact factor: 3.906

View more
  18 in total

1.  Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Authors:  Didier Meseure; Sophie Vacher; Kinan Drak Alsibai; Martine Trassard; André Nicolas; Renaud Leclere; Florence Lerebours; Jean Marc Guinebretiere; Elisabetta Marangoni; Rosette Lidereau; Ivan Bieche
Journal:  Cancer Microenviron       Date:  2016-07-09

2.  Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.

Authors:  Henrieta Scholtzova; Eileen Do; Shleshma Dhakal; Yanjie Sun; Shan Liu; Pankaj D Mehta; Thomas Wisniewski
Journal:  J Neurosci       Date:  2017-01-25       Impact factor: 6.167

3.  Distinctive Effects of GM-CSF and M-CSF on Proliferation and Polarization of Two Major Pulmonary Macrophage Populations.

Authors:  Christina Draijer; Loka Raghu Kumar Penke; Marc Peters-Golden
Journal:  J Immunol       Date:  2019-03-13       Impact factor: 5.422

4.  Intratumoral immunotherapy relies on B and T cell collaboration.

Authors:  Idit Sagiv-Barfi; Debra K Czerwinski; Tanaya Shree; Julian J K Lohmeyer; Ronald Levy
Journal:  Sci Immunol       Date:  2022-05-27

Review 5.  Renal Macrophages and Dendritic Cells in SLE Nephritis.

Authors:  Naomi I Maria; Anne Davidson
Journal:  Curr Rheumatol Rep       Date:  2017-11-09       Impact factor: 4.592

6.  Toll-Like Receptor 9 Deficiency Breaks Tolerance to RNA-Associated Antigens and Up-Regulates Toll-Like Receptor 7 Protein in Sle1 Mice.

Authors:  Teja Celhar; Hiroko Yasuga; Hui Yin Lee; Olga Zharkova; Shubhita Tripathi; Susannah I Thornhill; Hao K Lu; Bijin Au; Lina H K Lim; Thomas P Thamboo; Shizuo Akira; Edward K Wakeland; John E Connolly; Anna-Marie Fairhurst
Journal:  Arthritis Rheumatol       Date:  2018-10       Impact factor: 10.995

7.  Compromised Anti-inflammatory Action of Neutrophil Extracellular Traps in PAD4-Deficient Mice Contributes to Aggravated Acute Inflammation After Myocardial Infarction.

Authors:  Kaveh Eghbalzadeh; Leena Georgi; Theresa Louis; Haizhi Zhao; Ugur Keser; Carolyn Weber; Martin Mollenhauer; Andreas Conforti; Thorsten Wahlers; Adnana Paunel-Görgülü
Journal:  Front Immunol       Date:  2019-10-01       Impact factor: 7.561

8.  The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis.

Authors:  Heike Schmitt; Julia Ulmschneider; Ulrike Billmeier; Michael Vieth; Patrizio Scarozza; Sophia Sonnewald; Stephen Reid; Imke Atreya; Timo Rath; Sebastian Zundler; Melanie Langheinrich; Jürgen Schüttler; Arndt Hartmann; Thomas Winkler; Charlotte Admyre; Thomas Knittel; Christine Dieterich Johansson; Arezou Zargari; Markus F Neurath; Raja Atreya
Journal:  J Crohns Colitis       Date:  2020-05-21       Impact factor: 9.071

9.  Comprehensive Analysis of the Safety Profile of a Single-Stranded RNA Nano-Structure Adjuvant.

Authors:  Hyeong-Jun Park; Hae Li Ko; Dong-Hoon Won; Da-Bin Hwang; Yoo-Sub Shin; Hye-Won Kwak; Hye-Jung Kim; Jun-Won Yun; Jae-Hwan Nam
Journal:  Pharmaceutics       Date:  2019-09-07       Impact factor: 6.321

10.  Up-regulation of Toll-like receptors 7 and 9 and its potential implications in the pathogenic mechanisms of LMNA-related myopathies.

Authors:  Cristina Cappelletti; Franco Salerno; Eleonora Canioni; Marina Mora; Renato Mantegazza; Pia Bernasconi; Lorenzo Maggi
Journal:  Nucleus       Date:  2018       Impact factor: 4.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.